anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The present invention relates to a method for preparing medicinal granules, capsules or tablets for nourishing yin and the stomach from raw material through combined processing, wherein the raw material comprises micron ginseng rootlet powder, micron sodium copper chlorophyllin powder, micron hericium erinaceus powder, micron American ginseng powder, micron radix powder and micron dendrobium candidum powder processed via high-tech air flow superfine grinding, frozen-dried royal jelly powder, propolis powder, oligosaccharide powder, etc. Thus, the granules, capsules or tablets have the obvious functions of nourishing yin and the stomach and the effects of enhancing immunity, etc. With the granules, capsules or tablets, middle-aged and aged patients with intestine and stomach trouble can obtain hundreds of rich nutrient substances, such as vitamins, chlorophyll, etc. Meanwhile, due to the addition of micron powder ingredients of ginseng rootlets and dendrobium candidum called as 'oriental nourishing treasures', the granules, capsules or tablets strengthen the health care effects of nourishing yin and the stomach and beautifying faces. Therefore, the granules, capsules or tablets for nourishing yin and the stomach and prolonging life with Chinese characteristics are indeed good health care products designed specially for middle-aged and aged patients with stomach trouble such as chronic atrophic gastritis, etc. all over the world.
Patients receiving desvenlafaxine should have regular monitoring of blood pressure since increases in blood pressure were observed in clinical studies [see ADVERSE REACTIONS (6.1)]. Pre-existing hypertension should be controlled before initiating treatment with desvenlafaxine. Caution should be exercised in treating patients with pre-existing hypertension, cardiovascular, or cerebrovascular conditions that might be compromised by increases in blood pressure. Cases of elevated blood pressure requiring immediate treatment have been reported with desvenlafaxine.

Sustained blood pressure increases could have adverse consequences. For patients who experience a sustained increase in blood pressure while receiving desvenlafaxine extended-release tablets, either dose reduction or discontinuation should be considered [see ADVERSE REACTIONS (6.1)].
The Food and Drug Administration has been considering a potential federal restriction on menthol as a characterizing flavor in combustible cigarettes, a policy that would likely significantly reduce tobacco related disparities among Black adults who smoke menthol cigarette. However, in states where this policy has been enacted and menthol cigarettes are off the market, the tobacco industry has circumvented the restriction by introducing new non-menthol cigarettes that include WS-3, a chemical that acts as a cooling agent but without use of menthol. Our team is interested in understanding the extent to which WS-3 undermines a potential future menthol ban and the impact on the reduction in cigarettes smoked, particularly among Black adults who smoke.

The overall objective of this application is to obtain effect sizes and establish feasibility for an upcoming R01 submission. Specific aims include: Aim1: Determine the change in total cigarettes per day (CPD) when using menthol cigarettes, WS-3 cigarettes, and traditional non-menthol cigarettes. The primary comparison is between WS-3 and traditional non-menthol cigarettes. Aim 2: Understand the comparative abuse liability during ad libitum use of menthol cigarettes, WS-3 synthetic cooling agent cigarettes, and traditional non-menthol cigarettes. The study intervention involves providing study participants, who are all adult current smokers with no intention to quit or alter their cigarette smoking, with either menthol cigarettes, WS-3 synthetic cooling agent cigarettes, or traditional non-menthol cigarettes. All study products are commercially available. Participants will report on their usual number of cigarettes per day and will be provided a commensurate amount of study cigarettes to allow them to make a complete switch to the study product for the duration of the 6 week research study.
The study will be conducted as a single-arm trial consisting of participants enrolled in the test group. Each participant will receive a G7 CGM and their blood glucose levels will be continuously transmitted to the Dexcom Clarity cloud system for monitoring and data collection.
This is a pilot clinical trial examining the feasibility and efficacy of gemfibrozil treatment for smoking cessation. Adults with a desire to quit nicotine cigarette smoking will be recruited. Eligible participants will be randomly divided into two groups: those who receive gemfibrozil and waitlist controls. Screening will be conducted with a brief phone screen followed by a longer screening visit for those who qualify. During the screening visit, all study participants will provide demographic information and will be interviewed regarding smoking history. Procedures performed during the screening visit include a blood draw, urine pregnancy test, physical exam, clinical psychiatric interview, and measurement of exhaled carbon monoxide (CO). At baseline, participants will complete the Heavy Smoking Index (HSI) and the Brief Questionnaire of Smoking Urges (QSU-Brief). Participants will also complete the Quick Inventory of Depressive Symptoms-Self Rated (QIDS-SR) to assess symptoms of depression and changes in mood associated with smoking cessation will be assessed with the Concise Associated Symptoms Tracking (CAST) scale . Participants will work with the research clinician to set a target quit date within one week of the baseline session, and all participants will be provided written materials with guidance for smoking cessation as part of a smoking cessation counseling session. All participants will attend visits at the research clinic at 3 days and 4 weeks from target quit date to assess safety, adherence, and smoking status; participants will also receive additional smoking cessation counseling. Smoking status will be determined with exhaled breath CO and a single item questionnaire regarding the number of cigarettes smoked since target quit date and symptoms of depression and mood changes will again be measured. Medication side effects will be quantified using the Frequency, Intensity, and Burden of Side Effects Rating (FIBSER) scale. The final study visit will occur at 8 weeks after target quit date for completion of the HSI, QIDS-SR, CAST, FIBSER, exhaled breath CO, QSU-Brief, and smoking self-report.
Since the middle of the 20th century, the odontogenic keratocyst (OKC) has been one of the maxillofacial region's most contentious pathological phenomena. It was initially misdiagnosed as a primordial cyst. After that, because of its severe clinical behavior and tendency to recur, it was no longer considered to be a part of its classification, also known as a odontogenic tumor. Then, In 2017, the OKC are re-classified as a cystic lesion. But still there is debate about their management. So, this study will be enrolled with the following objectives: to describe how odontogenic keratocysts are managed, to Discover the most favorable approach to manage OKC with the need to stop it from happening again To categorize the odontogenic keratocyst management outcomes into to the subsequent groups: (1) total resolution, (2) partial resolution; (3) Recurrence.
Patients receive filgrastim (G-CSF) subcutaneously (SC) once daily for 6 days beginning 1 week after the start of chemotherapy (days 7-12). If chemotherapy begins on day 8, patients receive G-CSF SC on days 9-14.
PURPOSE:To collect only cartilages, by adding tracheas of animals to warm water having a specific temperature, adding a protease to it, stirring them. CONSTITUTION:600-800l water is added to 100-200kg tracheas of animal such as bovine, horse, sheep, etc., which is fed to a tank heated at 40-80 deg.C. A protease alone or a combination of proteases (e.g., vegetable enzyme such as dried papaya, latex, etc., enzyme produced by a culture, such as protease of ray fungus, animal enzyme such as pepsin, etc.) is added the tank, the tank is stirred, and protein digestion treatment is carried out. At the stage when connective tissue is digested, tracheal cartilages are collected. They are washed with water well, frozen and preserved. The protein digestion treatment is carried out in a pH range fittest to each of the enzymes (e.g., 5-7pH in dried papaya, latex, and papain, about 7pH in protease of ray fungus, and 1.5-2pH in pepsin). EFFECT:Since unnecessary connective tissue is eliminated, the cartilages are preserved and transported extremely advantageously.
The present invention relates to a medicine composition and a preparing method thereof for treating cardio-cerebrovascular disease, particularly to cerebral ischemic diseases. The medicine is prepared from ligustrazine or a ligustrazine salt compound capable of being physiologically accepted, astragaloside contains more than or equal to 20 wt. % of astragaloside IV and auxiliary addition components capable of being accepted in the medicine, wherein the astragaloside is used as an effective medicine component. In the effective medicine component, the weight ratio of the ligustrazine compound to the astragaloside is 1:0.2 to 1:5. During preparation, the extracted solution of the raw medicine hoantchy root which is used as raw material and is decocted by water is prepared and filtered; the filtered solution is adsorbed by macroporous resin, and the macroporous resin is orderly washed by water and 30% to 40% of ethanol solution to remove impurities; eluted solution containing 60% to 95% of ethanol is collected, the ethanol is removed, and the eluted solution is extracted by normal butanol to be washed by alkali water; the extracted solution is refluxed and defatted by aceton after the normal butanol is removed, and the astragaloside is obtained. The astragaloside, the ligustrazine compound and the corresponding auxiliary addition components are mixed to be prepared into a preparation. A test indicates that the medicine combined by the extracts of chemical medicines and natural medicines has synergistic effects in pharmacological activities.
Non-dust-forming, readily wettable, rapidly soluble granulates of any size are produced by (a) suspdning the substance to be granulated in a non-solvent or mixt. of non-solvents; (b) treating the suspension with small amts. of a liquid or mixt. of liquid which wets or dissolves the substance to form a multiphase system; (c) subjecting the mixt. to turbulent mixing until agglomerates are formed; and (d) separating and drying these. In a variant, the substance to be granulated is added continuously to the pre-formed multiphase system, the mixt. is shaken, and the agglomerates are sepd. and dried. The process can be used for dyes, optical brighteners, pharmaceuticals, pesticides, food-stuffs, detergents, photographic materials, leather chemicals, plastics, plastics additives, etc.
Rheumatoid arthritis (RA) severely lowers the life quality by progressively destructing joint functions and eventually causing permanent disability, representing a pressing public health concern. The pathogenesis of RA includes the excessive production of proinflammatory cytokines and harmful oxygen-derived free radicals, such as nitric oxide (NO), which constitute vital targets for precise diagnosis and effective treatment of RA. In this study, we introduce an advanced nanoagent that integrates the RA microenvironment-activatable photoacoustic (PA) imaging with multitarget synergistic treatment for RA. A highly sensitive organic probe with NO-tunable energy transformation and molecular geometry is developed, which enables strong near-infrared absorption with a turn-on PA signal, and the active intramolecular motion could further boost PA conversion. The probe is coassembled with an inflammation-responsive prodrug to construct the theranostic nanoagent, on which a macrophage-derived cell membrane with natural tropism to the inflammatory sites is camouflaged to improve the targeting ability to inflamed joints. The nanoagent could not only sensitively detect RA and differentiate the severity but also efficiently alleviate RA symptoms and improve joint function. The combination of activatable probe-mediated NO scavenging and on-demand activation of anti-inflammatory prodrug significantly inhibits the proinflammatory factors and promotes macrophage repolarization from M1 to M2 phenotype. This meticulously designed nanoagent ingeniously integrates RA-specific PA molecular imaging with synergistic multitarget therapy, rendering tremendous promise for precise intervention of RA-related diseases.
Head lice infestation occurs frequently, primarily in children 3 to 11 years of age. In recent years an increasing prevalence of lice infestation in schools, day care centres, and summer day camps is believed to be partly due to increasing lice resistance to currently available standard treatments for pediculosis (infestation with lice). There is a need for new effective backup treatments for this common condition of head lice infestation. This is a double-blind, randomized, parallel-group, study in several clinical centres comparing ivermectin as tablets to malathion 0.5% lotion in the treatment of head lice. All enrolled patients participate in the primary phase of the study up to the Day 15 evaluation. Patients who are still infested with lice at Day 15 (treatment failures) will enter an extension phase and be treated in a double-blind, fashion with the opposite treatment (ie ivermectin or malathion). The study hypothesis is that ivermectin will be more effective than malathion in clearing head lice infestation , as measured by the proportion of patients who are lice-free at Study Day 15.
1)	2,3-Dioxo-1,2,3,4-tetrahydro-quinoxalinyl derivatives of formula depicted wherein one of the radicals R1, and R2 is a group R5.  The other is a group of formula -CH(R6)-alk-R7 (Ia), -alk-CH(R6-R7 (Ib), -alk-N(R8)-X-R7 (Ic), -alk-N+(R8)(R9)-X-R7A- (Id), -alk-O-X-R7 (Ie) or -alk-S-X-R7 (If), R3, R4 and R5 are each independently of the others hydrogen, lower alkyl, halogen, trifluoromethyl, cyano or nitro.  R6 is unsubstituted or lower alkylated and/or lower alkanoylated amino.  R7 is hydrogen; an aliphatic, cycloaliphatic or heterocycloaliphatic radical; cyano; acyl derived from carbonic acid or from a semiester or semiamide of carbonic acid, from sulfuric acid or from an aliphatic or aromatic sulfonic acid or from phosphoric acid or from a phosphonic acid ester; amino that is unsubstituted or aliphatically or araliphatically substituted and/or substituted by aliphatic, araliphatic or aromatic acyl; or an aromatic or heteroaromatic radical.  R8 is hydrogen; an aliphatic or araliphatic radical; or acyl derived from an aliphatic or araliphatic carboxylic acid or from an aliphatic or araliphatic semiester of carbonic acid.  R7 and R8, together with X and the nitrogen atom bonding R8 and X, form an unsubstituted or substituted mono- or di-azaxycloalkyl, azoxacycloalkyl, azathiacycloalkyl or optionally oxidised thiacycloalkyl radical bonded via a nitrogen atom, or an unsubstituted or substituted, optionally partially hydrogenated aryl or heteroaryl radical.  R9 is an aliphatic or araliphatic radical.  R7-R9 together with X and the nitrogen atom bonding R8, R9 and X, form an unsubstituted or substituted quaternary heteroaryl radical bonded via the quaternary nitrogen atom, with A- being the anion of a protonic acid.  alk is lower alkylene, and X (unless, together with R7 and R8 and the nitrogen atom bonding R8 and X or together with the nitrogen atom bonding R8, R9 and X, it forms part of one of the mentioned ring systems) is a divalent aliphatic, cycloaliphatic or araliphatic radical or a direct bond.  Also included are the pharmaceutically acceptable salts thereof.  These compounds can be used in the preparation of a medicament for the treatment of pathological conditions that are responsive to blocking of AMPA, kainate and/or glycine binding sites of the NMDA receptor.
BACKGROUND: To date, surgery is the best approach to maximize a cure for symptomatic aspergilloma, but this is not without risk of both morbidity and mortality. The aim of this study is to present the characteristics and outcomes of 77 patients diagnosed with aspergilloma who underwent surgery at Chiang Mai University Hospital (CMUH), and to identify risk factors for composite major postoperative complications (CMPC).
METHODS: This is an observational retrospective cohort study carried out at CMUH over a period of 11 years from January 1, 2010, to February 28, 2021. Patient characteristics and postoperative outcomes were studied. The primary outcomes were categorized into CMPC. Univariable and multivariable risk regression analysis were used to identify risk factors of CMPC, with risk ratio (RR) and 95% confidence intervals being calculated.
RESULTS: There were 77 patients included in this study; 27 patients identified as having CMPC and 55 patients as a non-CMPC group. From the multivariable analysis, a factor associated with CMPC included perioperative FFP transfusion (risk ratio (RR) 1.01,95 % CI 1.01-1.02) and preoperative angiogram embolization (RR 8.42, 95 % CI 1.44-49.06) whereas immediate extubation (RR 0.22, 95% CI 0.06-0.81) was less likely to be associated with CMPC. There was a trend of increased risk of CMPC in patients received perioperative blood transfusion, but the data did not reach statistical significance.
CONCLUSIONS: This study has identified a need for patient profiling before embarking on lung surgery for aspergilloma, to predict outcomes and allocate resources appropriately for safer surgery.
The present invention relates to a composite series medicament of zanthoxylum seed kernel oil and pseudo-ginseng total saponin and a preparation technology thereof, and provides series preparations of oral liquor, tablets and capsules for treating cardio-cerebrovascular diseases. The composite series medicament is mainly prepared from zanthoxylum seed kernel oil and pseudo-ginseng total saponin. In the preparation technology, the present invention adopts adopt a zanthoxylum seed kernel oil separated preparation technology and a low-temperature separation, filtration and purification technology for zanthoxylum seeds, and thus, medical zanthoxylum seed kernel oil is processed. Simultaneously, thick paste or dry powder of ginseng total saponin is extracted out of pseudo-ginsheng medicinal material by a macropore resin method. The zanthoxylum seed kernel oil and the pseudo-ginseng total saponin are compounded. Thus, a series of Chinese patent medicines are prepared in bulk. The composite series medicament has the advantages of scientific preparation technology, cheap production cost, effective recipe, reasonable compatibility, and stable content, takes effects at quick efficiency, slow efficiency and gentle efficiency by times, and has obvious complementary action. The series of preparations can be used in a selection way, and have significant curative effects on cardio-cerebrovascular diseases in the primary period, treatment period and recovery period.
This study aims to evaluate the impact of integrating pain nursing with hospice care on the quality of life among patients with advanced lung cancer. This study involving 60 advanced lung cancer patients admitted from January 2022 to January 2023. Participants were randomly assigned to 2 groups: the observation group received a combination of pain nursing and hospice care, while the control group received standard nursing care. The study assessed changes in the numeric rating scale for pain, self-rating anxiety scale (SAS), self-rating depression scale (SDS), cancer fatigue scale (CFS), death attitude, and various quality of life dimensions as measured by the Quality of Life Questionnaire-Core 30. Post-intervention, both groups exhibited reductions in numeric rating scale, SAS, SDS, and CFS scores compared to baseline, with more significant improvements observed in the observation group (P < .05). Additionally, post-intervention scores for death attitude and Quality of Life Questionnaire-Core 30 domains (physical, cognitive, social, role, and emotional functioning, as well as overall health) increased in both groups, with the observation group showing greater improvements than the control group (P < .05). The combination of pain nursing and hospice care significantly reduces pain, anxiety, and depression, decreases cancer-related fatigue, and improves the quality of life and death attitudes in patients with advanced lung cancer, highlighting the benefits of this integrative approach in palliative care settings.
OBJECTIVE: To investigate the diagnostic significance of the combination of alpha-fetoprotein (AFP), serum abnormal prothrombin (PIVKA-II), and α-L-Fucosidase (AFU) in hepatocellular carcinoma (LC).
METHODS: A total of 580 cases of chronic hepatitis B patients were collected, including 124 cases of hepatitis B-related liver cancer patients treated in our hospital from March 2021 to December 2022, 325 cases of simple chronic hepatitis B patients, and 189 cases of hepatitis B cirrhosis patients from our hospital in the same period. We measured serum levels of AFP, PIVKA-II, and AFU using ELISA. Statistical analysis was performed using SPSS software, employing t tests, ANOVA. ROC curves were used to assess the effectiveness of the three markers alone and in combination for screening hepatitis B-associated liver cancer from patients with chronic hepatitis B.
RESULTS: The serum levels of AFP and PIVKA-II were significantly higher in the hepatitis B liver cancer group compared to the cirrhotic hepatitis B group and the chronic hepatitis B group, with statistically significant differences (P < .05). The AFU level in the hepatocellular carcinoma group was also significantly higher than that in the chronic hepatitis B group (P < .05). When individually tested, the AUC of PIVKA-II was the largest, followed by AFP, and AFU had the smallest AUC (P < .05). When combined, the AUC was the greatest, reaching XX, outperforming individual markers alone or their combinations. This suggests that combining AFP, AFU, and PIVKA offers improved sensitivity (86.5%) and specificity (97.8%) for liver cancer diagnosis. These findings indicate the potential clinical relevance of utilizing these biomarkers together for accurate detection and monitoring of liver cancer.
CONCLUSION: The combination of AFP, AFU, and PIVKA-II demonstrates improved diagnostic accuracy in early detection of hepatitis B-related hepatocellular carcinoma, particularly in patients with chronic hepatitis B complicated by cirrhosis. These findings have significant clinical implications, as early diagnosis enables timely intervention and treatment, potentially improving patient outcomes and guiding appropriate therapeutic strategies for affected individuals.
<P>PROBLEM TO BE SOLVED: To provide antigen-binding molecules with increased FC receptor binding affinity and effector function.  <P>SOLUTION: The antigen-binding molecules (ABMs) are provided. In a particular embodiment, recombinant monoclonal antibodies including chimeric, primatized or humanized antibodies specific to human CD20 are disclosed. Nucleic acid molecules encoding such ABMs, and vectors and host cells comprising such nucleic acid molecules are also provided. Methods for producing the ABMs, methods of using these ABMs in treatment of diseases are further provided. In addition, ABMs with modified glycosylation having improved therapeutic characteristics including antibodies with increased Fc receptor binding and increased effector function are provided.  <P>COPYRIGHT: (C)2010,JPO&INPIT